Tenax Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1967-01-01
- Employees
- 6
- Market Cap
- -
- Website
- http://www.tenaxthera.com
- Introduction
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
- Conditions
- Pulmonary Hypertension
- Interventions
- Drug: PlaceboDrug: TNX-103
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Tenax Therapeutics, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT05983250
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
🇺🇸U. of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
- Conditions
- Hypertension Pulmonary Secondary Heart FailureRight Sided Heart Failure With Normal Ejection FractionHeart Failure With Normal Ejection Fraction
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Tenax Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03624010
- Locations
- 🇺🇸
Stanford Healthcare, Stanford, California, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸UW Health University Hospital, Madison, Wisconsin, United States
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
- Conditions
- Hypertension Pulmonary SecondaryHeart Failure, Right SidedHeart Failure With Normal Ejection Fraction
- Interventions
- Drug: LevosimendanDrug: Matching Placebo
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Tenax Therapeutics, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03541603
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
- Conditions
- Heart Decompensation
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Tenax Therapeutics, Inc.
- Registration Number
- NCT02973620
Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
- Conditions
- Coronary Artery Bypass GraftingMitral Valve SurgeryLow Cardiac Output Syndrome
- Interventions
- Drug: LevosimendanDrug: Placebo
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Tenax Therapeutics, Inc.
- Target Recruit Count
- 882
- Registration Number
- NCT02025621
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Duke University Hospital, Raleigh, North Carolina, United States
🇺🇸Iowa Heart Center/ Mercy Medical Center, West Des Moines, Iowa, United States
Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI)
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Tenax Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00908063
- Locations
- 🇮🇱
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
🇨🇭Ospedale Regionale Lugano, Lugano, Switzerland
🇮🇱Hadassah Medical Center, Jerusalem, Israel
Study of Oxycyte in Severe Closed Head Injury
- Conditions
- Traumatic Brain Injury
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Tenax Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00174980
- Locations
- 🇺🇸
Virginia Commonwealth University Medical Center, Richmond, Virginia, United States